OptimumBank Holdings Inc. (NYSE American: OPHC)

The QualityStocks Daily Newsletter would like to spotlight OptimumBank Holdings Inc. (NYSE American: OPHC).

OptimumBank Holdings (NYSE American: OPHC) announced that Brean Capital, LLC has initiated equity research coverage of the company, with Director of Research Christopher Marinac assigning a Buy rating and an $8 price target. The report, distributed to Brean’s institutional client base, underscores growing recognition of the company’s business model, operating performance and long-term growth strategy, according to Chairman Moishe Gubin, who highlighted the initiation as a key step in expanding investor awareness.

To view the full press release, visit https://nnw.fm/iyrkB

OptimumBank Holdings Inc. (NYSE American: OPHC) is a single bank holding company that owns 100% of OptimumBank, a community bank headquartered in Fort Lauderdale, Florida. OptimumBank offers relationship-driven banking available in person, by phone, and online, serving both local and international clients by offering an alternative to the high fees and impersonal service of larger institutions. Its expertise in real estate and commercial lending has made it a preferred partner for borrowers seeking knowledgeable, accessible financial support.

Driven by disciplined execution and a commitment to local relationships, OptimumBank has experienced substantial organic growth, positioning itself as one of the fastest-growing community banks in the region. The company has surpassed $1 billion in total assets and remains focused on scaling efficiently, maintaining sound credit quality, and delivering strong returns for shareholders.

Looking ahead, the bank is embracing technology modernization while remaining grounded in the principles of relationship-based banking. A new open-architecture core platform, targeted loan expansion, and sustained deposit growth are key pillars of its forward strategy.

Products

OptimumBank offers a full suite of business and personal banking solutions, including Business Banking, Business Lending, SBA Lending Solutions, Treasury Management, and Personal Banking. Its lending focus includes commercial real estate, multifamily, construction, residential, and consumer loans.

The bank achieved Preferred Lender status with the Small Business Administration in just over two years—an uncommon accomplishment—and rapidly scaled its SBA lending operations from zero in record time. Its treasury services and deposit products are supported by a stable core funding base, with a growing percentage of noninterest-bearing demand deposits.

In late 2025, OptimumBank is rolling out a next-generation core banking platform with API-based architecture, enabling paperless processing, streamlined onboarding, and enhanced treasury management tools.

OptimumBank is deeply engaged in the community, providing support to organizations such as Habitat for Humanity of Broward, along with schools, synagogues, and many other nonprofits that are important to its customers and neighbors.

Market Opportunity

The U.S. community banking sector represents a multi-trillion-dollar opportunity, especially in underserved regions where local institutions continue to consolidate. South Florida’s real estate market and growing population create robust demand for personalized commercial lending, construction loans, and deposit services.

According to Mordor Intelligence, the U.S. commercial banking market is expected to grow from $732.5 billion in 2025 to $915.45 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4.56%. Within this landscape, OptimumBank is well-positioned to benefit from regional consolidation and rising customer dissatisfaction with national banks.

OptimumBank’s continued investments in talent, technology, and compliance infrastructure ensure scalability as it targets its next major milestone: becoming a top 200 publicly traded bank in the United States. The bank has maintained a track record of net recoveries in recent years, with no loan losses in over seven years and no defaults in its current loan portfolio. In addition, OptimumBank has near-zero exposure to long-dated, low-yield bonds, avoiding the balance sheet drag that has pressured many regional peers.

Leadership Team

Moishe Gubin, Chairman of OptimumBank Holdings, has been a director since 2010. He is also the CEO of Strawberry Fields REIT and previously served as CFO of Infinity Healthcare Management. Gubin is a licensed CPA in New York and the founder of the Midwest Torah Center.

Timothy Terry, President and CEO, has led OptimumBank since 2013 and has over 35 years of banking experience. He previously held senior roles at Enterprise Bank of Florida and other financial institutions, with a background in lending, branch administration, and sales.

Elliot Nunez, EVP and CFO, joined the bank in 2020. He previously served as CFO for Brickell Bank and Mellon United National Bank and worked at KPMG. Nunez is a licensed CPA and Chartered Global Management Accountant.

OptimumBank Holdings Inc. (NYSE American: OPHC), closed Monday's trading session at $5.49, up 1.105%, on 13,828 volume. The average volume for the last 3 months is 19,171 and the stock's 52-week low/high is $3.9005/$5.59.

Recent News

• OptimumBank Holdings Inc. (NYSE American: OPHC) - NetworkNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Gains Buy Rating and $8 Price Target as Brean Capital Initiates Coverage
• InvestorNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Gains Coverage From Alliance Global Partners With Buy Rating
• MissionIRNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Sets April 28 Annual Meeting And Investor Day

Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

Safe Pro Group (NASDAQ: SPAI) reported continued execution of its share repurchase program, with 400,000 shares repurchased as of April 17, 2026, representing approximately 3.5% of its public float under a $3.0 million authorization approved in December 2025. The company funded repurchases through operating cash flow and its strong balance sheet, which included $16.7 million in cash and no debt at year-end 2025, and said it may continue opportunistic buybacks while investing in its AI-enabled defense and security platform and long-term growth initiatives.

To view the full press release, visit https://ibn.fm/HcAav

Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), an artificial intelligence (AI)-enabled defense, security, and situational awareness solutions provider, today announced a positive update on its active share repurchase program, highlighting continued execution, disciplined capital allocation, and a clear commitment to enhancing shareholder value. On December 18, 2025, the Company’s Board of Directors approved and authorized a share repurchase program of up to $3.0 million of its outstanding common stock as part of its capital return strategy. Since the program’s inception, Safe Pro has been actively executing repurchases in the open market under this authorization. As of April 17, 2026, the Company has repurchased 400,000 shares of its common stock representing approximately 3.5% of Safe Pro’s approximately 11,600,000 shares held by non-affiliates. These open market purchases reflect management’s confidence in the Company’s intrinsic value, AI-driven growth strategy, and long-term growth outlook.

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Monday's trading session at $4.46, up 1.1338%, on 132,088 volume. The average volume for the last 3 months is 216,292 and the stock's 52-week low/high is $2.39/$9.1599.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - Safe Pro Reports on Share Repurchase Program, Reinforcing Commitment to Shareholder Value and Capital Return
• DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Repurchases 400,000 Shares Under $3 Million Buyback Program
• DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Demonstrates AI Drone Threat Detection in U.S. Army Live Fire Exercise

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s strategy as it advances its NRX-100 drug candidate and seeks regulatory support to address severe depression, PTSD and suicidality.

To view the full press release, visit https://ibn.fm/lei9r

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Monday's trading session at $3.2, up 25.4902%, on 4,591,170 volume. The average volume for the last 3 months is 1,067,262 and the stock's 52-week low/high is $1.62/$3.84.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development
• DefenseNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications
• MissionIRNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch

Lantern Pharma Inc. (NASDAQ: LTRN)

The QualityStocks Daily Newsletter would like to spotlight Lantern Pharma Inc. (NASDAQ: LTRN).

Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek feedback on proposed protocol amendments to its Phase 2 HARMONIC(TM) trial evaluating LP-300 in non-small cell lung cancer. The proposed changes include focusing enrollment on EGFR Exon 21 L858R patients, shifting to a single-arm study design and extending treatment cycles, supported by emerging clinical data showing an 8.3-month median progression-free survival and encouraging response rates in this difficult-to-treat population.

To view the full press release, visit https://ibn.fm/CUsmq

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR® (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (ADC) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR® platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic™) for non-small cell lung cancer (NSCLC) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (TNBC), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (NHL) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

• LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
• LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
• LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
• CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

Lantern Pharma Inc. (NASDAQ: LTRN), closed Monday's trading session at $2.76, up 10.8434%, on 244,448 volume. The average volume for the last 3 months is 1,310,107 and the stock's 52-week low/high is $1.11/$5.7441.

Recent News

• Lantern Pharma Inc. (NASDAQ: LTRN) - BioMedNewsBreaks - Lantern Pharma (NASDAQ: LTRN) Schedules FDA Type C Meeting For HARMONIC Trial Amendments
• AINewsBreaks - Lantern Pharma (NASDAQ: LTRN) Launches withZeta.ai Platform, Opens New Revenue Stream
• AINewsBreaks - Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader

Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that early clinical trials revealed a disconnect between IV-based delivery and the daily realities of patients with chronic rare diseases, prompting a shift toward a more practical, home-based subcutaneous approach. According to Schaber, operational challenges such as travel burden, treatment scheduling, and patient retention should be viewed as strategic signals rather than logistical obstacles. He notes that reformulation—while adding complexity to development timelines—can ultimately de-risk later-stage trials and enhance long-term adoption by aligning therapies with how patients live and manage their conditions. The article underscores a broader industry shift toward designing treatments that balance efficacy with convenience, accessibility, and patient experience, reinforcing the role of delivery innovation in successful clinical outcomes.

To view the full article, visit https://ibn.fm/QM3YT

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Monday's trading session at $1.38, up 10.4%, on 917,631 volume. The average volume for the last 3 months is 356,537 and the stock's 52-week low/high is $1/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
• Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
• Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)

The QualityStocks Daily Newsletter would like to spotlight MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF).

Disseminated on behalf of MindBio Therapeutics Corp., may include paid advertisements.

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

• The Intox Collect(TM) technology enhances the company’s ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment.
• MindBio says the platform broadens detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants.
• The company’s AI model currently uses more than 50 million data points, with management expecting that figure to increase further.
• MindBio is developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026.
• Target industries include mining, aviation, construction, law enforcement, and any environments where intoxication testing is frequently required for safety and compliance.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) , a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection, is expanding its artificial intelligence-based intoxication detection platform with the rollout of Intox Collect(TM), a new software tool designed to broaden the company’s data collection and analytics capabilities across a wider range of substances that affect the central nervous system.

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company developing and commercializing artificial intelligence-powered health prediction technologies that use the human voice as a diagnostic input. The company’s platform is centered on acoustic biomarker analysis, transforming speech into measurable physiological insights that can be used to detect drug and alcohol intoxication and support broader health monitoring applications. By leveraging voice as a non-invasive data source, MindBio is advancing a scalable approach to real-time diagnostics.

The company’s technology is built on clinical trials and large-scale data analysis, with predictive models trained on more than 50 million data points and supported by multiple studies demonstrating high levels of accuracy in intoxication detection. This foundation enables both consumer-facing and enterprise-grade applications, positioning MindBio to address use cases ranging from personal awareness tools to workforce safety and regulatory compliance in high-risk industries.

MindBio is advancing toward commercialization through a dual-channel strategy that includes a launched consumer application and enterprise solutions in development for large-scale deployment. Recent company activity highlights a transition toward field implementation, particularly within the mining sector, alongside expansion into industries such as aviation and construction. The platform is also being developed for broader applications in telehealth and remote monitoring.

The company is headquartered in Melbourne, Australia.

Products and Platform

Booze AI (Consumer Application)

MindBio’s Booze AI application enables users to estimate blood alcohol concentration using voice input via a smartphone or web-based interface. The platform combines speech analysis with behavioral tasks to provide real-time insights into intoxication levels and performance impairment, supporting awareness and harm prevention through accessible, non-invasive testing.

Enterprise Solutions

MindBio is developing enterprise-grade solutions for safety-critical industries such as mining, aviation, and construction, where impairment detection is essential. These solutions are designed for scalable, real-time screening of drug and alcohol intoxication, addressing limitations of traditional methods that are invasive, time-consuming, and operationally restrictive at scale. Recent developments include expansion into South America, deployment of engineering teams, and preparation for initial field testing of enterprise solutions in mining environments.

Core Technology and Platform

The company’s platform is built on proprietary AI models trained on more than 50 million data points and over 140 acoustic parameters extracted from human speech. This acoustic biomarker engine enables rapid, non-invasive detection of physiological and cognitive changes, delivering results in seconds with demonstrated accuracy exceeding 85% for BAC prediction and approximately 88% for intoxication classification, as validated through controlled studies and real-world testing.

To support enterprise adoption, MindBio is developing an integrated Edge AI hardware-software platform, including voice-initiated, touchless kiosk-based systems for on-site deployment with real-time, on-device analysis and audit-ready data capture for compliance. The platform is designed to support both hardware sales and recurring software revenue, while also expanding into adjacent applications such as telehealth, remote monitoring, and multi-substance detection using the same underlying voice analysis technology.

Market Opportunity

MindBio is targeting a total addressable market of approximately $47 billion in workplace safety and substance testing, driven by regulatory requirements across industries such as mining, aviation, construction, and transportation. The global workplace drug testing market is estimated at $15.4 billion, reflecting continued demand for solutions that can improve efficiency, scalability, and compliance in safety-critical environments.

The company also operates within broader high-growth markets, including telehealth and remote monitoring, projected to reach $285 billion, and consumer health applications estimated at $18.2 billion. These opportunities are supported by larger trends in digital health and alcohol-related harm, including a $547 billion digital health market and an estimated $1.6 trillion global cost associated with alcohol-related harm, reinforcing demand for scalable, non-invasive diagnostic technologies.

Leadership Team

Justin Hanka, Founder & CEO, brings a background in merchant and investment banking, with multiple successful exits and a focus on advancing technologies that have a meaningful impact on global health outcomes.

Gavin Upiter, Non-Executive Chairman, brings more than 25 years of experience in the pharmaceutical industry, including founding Generic Health, which was later sold to Lupin.

John Dinan, CFO, brings experience as a public and private company chief financial officer, with expertise in private equity and mergers and acquisitions, as well as a background as an Olympic sprinter and record holder.

Paul Lopez, Chief Engineer, brings more than 20 years of experience working with leading technology companies, with expertise in artificial intelligence and software design, and leads the company’s global engineering team.

MindBio Therapeutics Corp. (OTCQB: MBQIF), closed Monday's trading session at $0.4, up 12.6761%, on 400 volume. The average volume for the last 3 months is 10,140 and the stock's 52-week low/high is $0.28/$2.4435.

Recent News

• MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) - MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)
• BioMedNewsBreaks - MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Engages Venture Liquidity Providers for Market-Making Services
• MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World's First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening

AI Maverick Intel Inc. (OTC: AIMV)

The QualityStocks Daily Newsletter would like to spotlight AI Maverick Intel Inc. (OTC: AIMV).

Snapchat’s parent company, Snap Inc., has announced a major round of layoffs, cutting about 1,000 jobs, which is around 16 percent of its workforce. The company is also removing hundreds of open job listings as it shifts its focus toward a leaner and more efficient way of operating. This decision reflects a growing trend in the tech industry where companies are turning to artificial intelligence to handle routine tasks that were once done by humans. Chief Executive Officer Evan Spiegel explained that the company is going through what he called a “crucible moment.” In simple terms, this means Snap is at a critical turning point and must make tough decisions to survive and grow. One of the main goals behind the layoffs is to reduce yearly costs by about $500 million. At the same time, the company wants to improve how work gets done by using AI tools. As companies invest heavily in AI, they are also cutting costs in other areas, including staffing. This means that more job cuts could happen in the near future across the industry. Snap’s latest move highlights a clear shift in the workplace. Artificial intelligence is no longer just an added tool; it is becoming central to how companies operate. While this may lead to faster and more efficient systems, it also raises concerns about job security as traditional roles continue to shrink. When tech startups like AI Maverick Intel Inc. (OTC: AIMV) incorporate AI from the get-go, the message is clear: the jobs of the future are bound to be heavily influenced by AI, and employees need to adapt or find it harder to secure jobs. 

AI Maverick Intel Inc. (OTC: AIMV) is a technology-forward company focused on transforming how businesses acquire and engage customers through artificial intelligence. With a growth strategy centered on acquiring revenue-generating businesses, the company leverages its proprietary platform to deliver scalable, automated solutions across key sectors including healthcare, biotech, insurance, and transportation.

The company’s vision is to eliminate friction from the customer acquisition process by replacing traditional, resource-heavy outreach with intelligent, automated engagement. Its mission is to empower organizations to connect with their ideal audiences at high velocity, using real-time insights and personalized communication powered by machine learning.

AI Maverick Intel is committed to creating long-term value through innovation, efficiency, and strategic partnerships that enhance operational performance and accelerate growth.

The company is headquartered in Dallas, Texas.

Platform & Operations

AI Maverick’s proprietary technology powers a fully automated, AI-driven prospecting engine that enables businesses to scale customer acquisition without expanding headcount. In July 2025, the company launched its enhanced platform, capable of managing both transactional and consultative sales engagements with human-like fluency.

Key components include:

• Comprehensive Contact Intelligence – Aggregates millions of structured and unstructured data points to build dynamic profiles highlighting job changes, buying intent, and preferences.
• Context-Aware Messaging – Adaptive language models tailor tone, timing, and delivery channel for each interaction to maximize engagement.
• Autonomous Sales Dialogues – Manages discovery questions, handles objections, and schedules follow-ups, traditionally handled by sales reps.

This solution supports two-way communication across the full sales funnel—from quote generation and renewals to needs analysis and solution recommendations. The platform is designed to accelerate deal flow and reduce acquisition costs, with typical deployments completed in under a day.

AI Maverick’s transition into an AI-first company followed its acquisition of the AI Maverick platform in May 2025 and a formal rebrand later that month. The company’s public identity now aligns with its operational direction, targeting continued growth through platform scale and strategic business combinations.

Market Opportunity

AI Maverick Intel operates within the rapidly growing artificial intelligence in marketing sector, where machine learning is being widely adopted to personalize customer engagement, optimize ad performance, and automate sales interactions. According to Grand View Research, the global AI in marketing market was valued at $20.44 billion in 2024 and is projected to reach $82.23 billion by 2030, representing a compound annual growth rate (CAGR) of 25.0% from 2025 to 2030.

This growth is being driven by increased demand for individualized consumer experiences, expanded adoption of social networking platforms, and the continued rise of online shopping. North America currently leads the market with a 32.4% revenue share, while Asia Pacific is expected to see the fastest growth. Key applications include content curation, dynamic ad creation, and real-time audience targeting, which are consistent with the platform’s intended use cases.

As companies across industries prioritize speed, accuracy, and scale in reaching their target audiences, AI Maverick’s automation-first approach positions it to capitalize on a multi-billion-dollar transformation in how modern customer acquisition is executed.

Leadership Team

Wayne Cockburn, Chief Executive Officer, is an experienced business executive with over 25 years of board experience across public and private companies in both the U.S. and Canada. He has held senior leadership roles in healthcare and financial services firms, with past titles including Executive Vice President at MedX Health Corp., Chairman of Niiomed Inc., and President of Pathway Health Corp. He is skilled in M&A, capital markets, governance, and startup development, and holds a bachelor’s degree from York University’s Glendon College.

AI Maverick Intel Inc. (OTC: AIMV), closed Monday's trading session at $0.1, up 6.383%, on 100 volume. The average volume for the last 3 months is 9,290 and the stock's 52-week low/high is $0.012/$0.15.

Recent News

• AI Maverick Intel Inc. (OTC: AIMV) - Snapchat Slashes 1,000 Jobs Saying AI is Taking Over Repetitive Tasks
• Survey Says AI Has Replaced 20% of Full-Time Roles in the US
• CHROs Say AI is Transforming, Not Replacing Entry-Level Jobs

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

• Beeline is integrating its mortgage and title platform into a broader AI-driven real estate ecosystem, with embedded finance emerging as an important distribution model in residential real estate.
• The SRG partnership targets up to 2,000 home financings in a defined, multi-year development pipeline.
• The company’s AI tools aim to reduce friction in underwriting and borrower qualification, with younger buyers and real estate investors remaining a core demographic focus.
• Early share price performance suggests investor responsiveness to execution milestones and partnerships.

Beeline Holdings (NASDAQ: BLNE) , a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, is advancing its strategy to embed mortgage and title services directly into digital real estate platforms, with a newly announced partnership with Structured Real Estate Group (“SRG”). The agreement, detailed in a company press release, positions Beeline’s technology inside SRG’s AI-driven property ecosystem, allowing users to move from property selection to financing without leaving a single interface ( https://ibn.fm/DEI7p ).

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Monday's trading session at $2.19, off by 7.9832%, on 682,184 volume. The average volume for the last 3 months is 587,947 and the stock's 52-week low/high is $0.6202/$4.65.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - Beeline Holdings Inc. (NASDAQ: BLNE) Expands Embedded Mortgage Strategy Through SRG Partnership
• CryptoNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Partners With Structured Real Estate Group to Integrate Embedded Mortgage Platform Into AI-Driven Real Estate Ecosystem
• Beeline Holdings Inc. (NASDAQ: BLNE) Q4 Revenue Surge Portends 2026 Growth

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Massimo Group (NASDAQ: MAMO) announced the appointment of Quenton Petersen as Chief Executive Officer, effective April 14, 2026, with David Shan transitioning to Executive Chairman while remaining actively involved in the Company’s strategic direction. Petersen, a nine-year veteran of the company, emphasized continued growth across utility vehicles and electric mobility, alongside a disciplined evaluation of opportunities to integrate advanced technologies such as AI-enabled features and expand into applications including facility operations and smart mobility.

To view the full press release, visit https://ibn.fm/j3rCs

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Monday's trading session at $1.14, off by 7.3171%, on 1,183,879 volume. The average volume for the last 3 months is 2,644,297 and the stock's 52-week low/high is $0.85/$5.59.

Recent News

• Massimo Group (NASDAQ: MAMO) - InvestorNewsBreaks - Massimo Group (NASDAQ: MAMO) Appoints Quenton Petersen as CEO, Transitions David Shan to Executive Chairman
• AINewsBreaks - Massimo Group (NASDAQ: MAMO) Enters Strategic Cooperation With AIBO Robotics to Advance AI-Driven Automation and Smart Mobility
• Toyota's bZ EV is Threatening Tesla's Dominance in the US

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising.

ESGold (CSE: ESAU) (OTCQB: ESAUF) announced it will commence sonic core drilling of historic heap leach pads at its Santa Fe Gold Mine Project in Nevada’s Walker Lane, with permits expected shortly and mobilization of a Boart Longyear LS 450 rig to follow. The planned program includes 95 holes totaling 1,740 meters to evaluate potential gold and silver resources from pads associated with historic production of approximately 359,000 ounces of gold and 700,000 ounces of silver, with the company highlighting the potential for low-cost reprocessing to enhance project economics and support future production and cash flow growth.

To view the full press release, visit https://ibn.fm/LX3wW

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

ESGold Corp. (OTCQB: ESAUF), closed Monday's trading session at $0.38, off by 0.7832898%, on 332,000 volume. The average volume for the last 3 months is 212,740 and the stock's 52-week low/high is $0.31/$1.1.

Recent News

• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) - MiningNewsBreaks - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) to Drill Historic Heap Leach Pads At Santa Fe Project
• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Nears Drill Program Start as Part of Multi-Pronged Gold Revenue Strategy
• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Doubles Down on Montauban Project Development as 2026 Gold Prices Remain in Record High Territory

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising.

Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) announced it will soon commence sonic core drilling of historic heap leach pads at its Santa Fe Gold Mine Project in Nevada’s Walker Lane, with permits expected shortly and mobilization of a Boart Longyear LS 450 rig to follow. The program will include 95 holes totaling 1,740 meters to evaluate potential gold and silver resources from pads that previously supported production of approximately 359,000 ounces of gold and 700,000 ounces of silver, with the company highlighting the potential for low-cost reprocessing to enhance project economics and support its strategy to expand resources, cash flow and long-term production.

To view the full press release, visit https://ibn.fm/8wX1H

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Monday's trading session at $0.3155, off by 0.910804%, on 388,834 volume. The average volume for the last 3 months is 1,095,290 and the stock's 52-week low/high is $0.0321/$0.3981.

Recent News

• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) - RockBreaks - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) to Drill Historic Heap Leach Pads At Santa Fe Project
• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Gains Relevance as Inflation, Conflict and Central-Bank Demand Reshape Gold
• MiningNewsBreaks - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Reports Strong Cyanide Extraction Results at West Santa Fe Project

Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF)

The QualityStocks Daily Newsletter would like to spotlight Planet Ventures Inc. (CSE: PXI) (OTCQB: PNXPF).

Disseminated on behalf of Planet Ventures Inc., may include paid advertisements.

This article has been disseminated on behalf of Planet Ventures Inc. and may include paid advertising.

Planet Ventures (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) announced it has adopted a Disclosure, Confidentiality and Insider Trading Policy to strengthen compliance with Canadian securities laws, prevent selective disclosure and ensure proper handling of material information, while also updating its Investment Policy to include a focus on space technology and infrastructure, artificial intelligence, robotics and other disruptive technologies, reflecting the company’s commitment to innovation across emerging sectors.

To view the full press release, visit https://ibn.fm/D5k85

Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) is an investment issuer focused on identifying and investing in innovative companies operating within the space and aerospace sectors. The company’s strategy is centered on providing shareholders with exposure to emerging, high-growth opportunities, including private companies that are typically accessible primarily to venture capital and institutional investors.

The company employs a portfolio-driven investment approach, seeking to build a diversified base of investments across multiple segments of the space economy. Its activities are focused on sourcing and participating in opportunities globally, leveraging its network and experience to access and evaluate potential investments aligned with long-term growth trends in the sector.

Planet Ventures aims to create shareholder value through strategic capital allocation into companies developing technologies and services that support the expanding commercial space ecosystem.

The company is headquartered in Vancouver, British Columbia.

Portfolio

Planet Ventures operates as an investment platform, deploying capital into companies across the space and aerospace value chain, including infrastructure, software, energy, robotics, and emerging applications.

The company’s investment thesis is based on the view that many of the most significant opportunities in the space sector remain private and are not directly accessible to public market investors. Through its investment approach, Planet Ventures provides shareholders with indirect exposure to these companies, including through positions that may offer access to private businesses typically only available to venture capital and institutional investors.

Launch & Infrastructure

Planet Ventures has gained exposure to Relativity Space Inc. through an investment in MCXGP Relativity Fund I LLC, a special purpose vehicle that participated in the company’s most recent financing round. Relativity Space is developing reusable launch vehicles, including the Terran R rocket, designed for mid-to-heavy lift missions and low Earth orbit satellite deployment.

The company has also invested in Mantis Space Corp., which is developing orbital energy infrastructure intended to deliver power to satellites and other space-based systems.

Software & Data Platforms

Planet Ventures has made a strategic investment in Antaris Inc., an AI-powered platform designed to support the design, simulation, and operation of satellite constellations. The platform is intended to streamline mission development and enable software-driven approaches to space operations.

Emerging Applications & Robotics

Planet Ventures has invested in Galactic Resource Utilization Space Inc. (GRU Space), a company focused on developing habitat infrastructure for use beyond Earth, including concepts related to space tourism.

The company has also invested in General Astronautics, a space robotics company developing autonomous systems designed to operate in microgravity environments to support research and manufacturing activities in space.

Market Opportunity

Planet Ventures operates within the global space economy, which is valued at approximately $626 billion in 2025 and is projected to exceed $1.8 trillion by 2035, according to data from the World Economic Forum. Growth in the sector is being driven by increasing commercialization (with commercial revenues accounting for 78% of the total market, according to the Space Foundation), as well as expanding satellite applications, infrastructure development, and national security initiatives.

The space economy encompasses a wide range of activities that can be broadly divided into upstream and downstream segments. Upstream activities include launch systems, satellite manufacturing, and on-orbit operations, while downstream activities include satellite communications, navigation and positioning services, and earth observation.

The satellite segment represents a significant portion of the overall market, alongside growing areas such as space infrastructure, software platforms, and emerging commercial applications. Increased participation from private companies continues to play a central role in the expansion of the sector.

Leadership Team

Etienne Moshevich, Chief Executive Officer, has a background in capital markets and private investing and has focused on evaluating, financing, and advising early-stage and growth companies across multiple sectors. His role includes portfolio strategy, capital allocation, and investor relations, with a focus on aligning management teams and shareholders toward long-term outcomes.

Desmond Balakrishnan, Executive Director, is a partner at McMillan LLP and an experienced capital markets and securities lawyer. He has advised clients across multiple industries and has experience in private equity investments, public offerings, mergers and acquisitions, and listed company advisory.

Brian Shin, Chief Financial Officer, specializes in financial reporting, corporate finance, auditing, corporate strategy, and risk management. He provides accounting and consulting services to both public and private companies and has served as CFO for multiple organizations in Canada.

Planet Ventures Inc. (OTCQB: PNXPF), closed Monday's trading session at $0.2489, off by 14.1724%, on 1,436 volume. The average volume for the last 3 months is 205,870 and the stock's 52-week low/high is $0.0274/$0.5.

Recent News

• Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) - InvestorNewsBreaks - Planet Ventures Inc. (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) Adopts Disclosure Policy And Updates Investment Strategy
• InvestorNewsBreaks - Planet Ventures Inc. (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) Invests in Relativity Space Financing Round
• NetworkNewsBreaks - Planet Ventures Inc. (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) Invests $250,000 In AI-Driven Space Software Company Antaris